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A b s t r a c t
Heart failure (HF) is a leading cause of hospitalisation and death among older adults in high-income countries. HF is often  
accompanied by comorbid conditions, and patients hospitalised for HF commonly die or are readmitted in the weeks follow-
ing hospital discharge. The objectives of this paper are to discuss the burden of HF hospitalisations in healthcare systems and 
to review strategies that reduce hospitalisations and death in this condition. 
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INTRODUCTION
Heart failure (HF) is one of the most common causes of hospi-
talisation in older adults and accounts for more than 1 million 
hospitalisations in Europe each year [1–3]. Disproportionately 
burdening the elderly, HF affects about 10% of men and 8% of 
women over the age of 60 years [2]. With increments in age, 
the proportion of hospitalisations for HF increases relative to 
hospitalisations for other diagnoses (Fig. 1) [3]. The five-year 
mortality is approximately 50% higher than that of many 
cancers [4]. With advances in medical and device therapy, 
the age-adjusted death rate has declined and the mean age 
at death from HF has risen, leaving a larger proportion of 
patients living with advanced HF [5–8]. The importance of 
implementing evidence-informed interventions to improve 
the quality of life and decrease avoidable hospitalisations has 
never been greater.
EPIDEMIOLOGY
Patients hospitalised for HF are at high risk of death and read-
mission, and approximately 25% of HF patients are rehospi-
talised within a month of discharge [9, 10]; readmission rates 
fairly static over the past decade in some national registries 
[11]. Hospitalisations and readmissions account for 70% of the 
direct healthcare costs in HF in high-income countries [12]. 
About half of all readmissions are due to worsening HF and 
the other half due to comorbidities such as kidney disease and 
diabetes [13–20]. Functional limitation, frailty, psychosocial 
and socioeconomic factors limiting adherence to medications, 
self-monitoring, and follow-up may also impact the overall 
readmission rate [21–23].
There are two high-risk periods following hospitalisation 
for HF: one is the transitional care period (one to two months 
after hospital discharge), when patients face a 25% risk of 
readmission, and the other is during the last two months of 
life, when the risk of readmission increases to 50% [24]. The 
period between these two is the plateau phase, a period of 
relative stability, when patients are at a 15% risk of readmission 
[24]. It is estimated that at least 25% of early HF readmissions 
within the first post-discharge month may be avoided through 
optimisation of care [25].
STRATEGIES TO IMPROVE OUTCOMES  
AFTER HOSPITALISATION FOR HF
There has been steady progress in the development of thera-
pies for HF, with interventions that address the underlying 
causes of HF (e.g. coronary revascularisation, heart valve 
replacement, treatment of cardiomyopathies, etc.); drugs that 
decrease death and readmission; cardiac resynchronisation 
therapy (CRT) and implantable cardioverter-defibrillators 
(ICDs) that decrease death and also readmissions for selected 
patients; and mechanical circulatory support or transplant 
for a small subset of patients with HF. The use of healthcare 
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services that are evidence-informed is an underemphasised 
but equally important strategy in decreasing death and read-
mission [26–38]. 
Medical therapies
Heart failure is classified according to left ventricular ejection 
fraction (LVEF) as reduced (< 40%), preserved (> 50%), or 
mid-range (40%–50%). In randomised controlled trials (RCTs), 
b-blockers as a class result in significant reductions in death in 
HF with reduced ejection fraction (HFrEF). The COMET trial 
demonstrated that carvedilol was superior to metoprolol in 
patients with LVEF < 35%, who had been treated optimally 
with diuretics and angiotensin-converting enzyme inhibi-
tors (ACEIs) [26]. All-cause mortality after a mean duration 
of 58 ± 6 months was 34% in patients receiving carvedilol 
(target dose, 25 mg twice daily) and 40% in those treated with 
metoprolol (target dose, 50 mg twice daily) (hazard ratio [HR] 
0.83; 95% confidence interval [CI] 0.74–0.93), with mortality 
benefit driven by a reduction in cardiovascular death. The 
incidence of adverse effects and drug withdrawals did not 
differ between the two study groups. 
There have been no other head-to-head comparisons 
of b-blockers in HFrEF. A pairwise network meta-analysis 
of mainly indirect comparisons of b-blockers demonstrated 
mortality benefits compared with placebo after a median 
of 12 months (odds ratio 0.69; 95% CI 0.56–0.80), with 
no significant differences between b-blockers for the risk of 
death, sudden cardiac death, death due to pump failure, or 
drug discontinuation [27]. This meta-analysis showed that 
among b-blockers, carvedilol demonstrated the greatest 
reduction in mortality among HF patients, and also had the 
best tolerability, although not significantly different from other 
b-blockers. Among the b-blockers tested, carvedilol, bisopro-
lol, and sustained-release metoprolol had the widest range 
of clinical applications, so these three specific b-blockers are 
recommended as first-line therapy in patients with HFrEF. 
Angiotensin-converting enzyme inhibitors are widely 
used in HF. Several RCTs have demonstrated risk reduction 
in both mortality and HF readmission. An individual patient 
data meta-analysis [28], including more than 11,000 patients 
randomly assigned to treatment or placebo and followed for 
an average of 35 months, showed that ACEIs significantly 
decreased both mortality and readmission risk. The benefits 
were observed early after the initiation of therapy, persisted 
long-term, and were largely independent of age, sex, and use 
of diuretics, acetylsalicylic acid, and b-blockers. There was 
a trend towards a greater reduction in the risk of death or 
HF readmission in patients with lower ejection fractions [29].
The benefit of angiotensin receptor-neprilysin inhibitors 
(ARNIs) was demonstrated in PARADIGM-HF, an RCT that ran-
domised patients with HFrEF and New York Heart Association 
(NYHA) class II–IV to sacubitril/valsartan 200 mg twice daily 
or enalapril 10 mg twice daily, in addition to recommended 
therapy [28]. The primary outcome was a composite of death 
from cardiovascular causes or hospitalisation for HF. After 
a median follow-up of 27 months, the primary outcome oc-
curred in 21.8% of patients from the sacubitril/valsartan arm 
and 26.5% in the enalapril arm (HR 0.80; 95% CI 0.73–0.87). 
The proportions of patients who died from any cause were 
17.0% and 19.8%, respectively (HR 0.84; 95% CI 0.76–0.93), 
and from cardiovascular causes, 13.3% and 16.5%, respec-
tively (HR 0.80; 95% CI 0.71–0.89). Relative to enalapril, 
sacubitril/valsartan decreased the risk of hospitalisation for HF 
by 21% (HR 0.79; 95% CI 0.71–0.89). Adverse effects of sacu-
bitril/valsartan were hypotension and angioedema, with lower 
proportions of renal impairment, hyperkalaemia, and cough 
compared with the enalapril group [29]. This class of agents is 
now recommended as second-line therapy instead of ACEIs if 
patients with HFrEF are symptomatic on maximally tolerated 
doses of ACEIs. A recent RCT, PIONEER-HF, demonstrated 
the safety of initiating ARNIs during hospitalisation for acute 
decompensated HF, but while there was an improvement in 
Figure 1. Proportion of hospitalisations due to heart failure (HF), stratified by age and sex (modified from [3])
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the biomarker profile, the study was not statistically powered 
to detect a difference in clinical outcomes [30].
Several RCTs have demonstrated a decrease in death and 
hospitalisation with mineralocorticoid receptor antagonists 
(MRAs) in the setting of HFrEF, defined as an ejection frac-
tion < 35% in these particular trials. This includes the RALES 
trial [31], in which spironolactone decreased all-cause death 
(HR 0.70; 95% CI 0.60–0.82); the EPHESUS trial [32], in which 
epleronone decreased all-cause death (relative risk [RR] 0.85; 
95% CI 0.75–0.96); and the EMPHASIS trial [33], in which 
epleronone decreased the composite outcome of cardiovascu-
lar death or HF hospitalisation (HR 0.63; 95% CI 0.54–0.74).
Ivabradine is an inhibitor of the cardiac pacemaker If 
current in the sinoatrial node, and it decreases the heart rate 
without reducing blood pressure [34]. The drug does not affect 
atrioventricular or intraventricular conduction times, myocar-
dial contractility, or ventricular repolarisation [34]. The SHIFT 
trial [35] evaluated the efficacy of ivabradine in patients with 
HFrEF, classified as NYHA class II–IV. Patients were required to 
have normal sinus rhythm, a ventricular rate > 70 bpm, and 
hospitalisation in the preceding year. Patients on ivabradine 
had a significant reduction in the composite endpoint of 
death and HF hospitalisation (24% in the ivabradine group 
and 29% in the placebo group; HR 0.82; 95% CI 0.75–0.90), 
but this was driven mainly by a reduction in HF hospitalisa-
tion (16% vs. 21%, respectively; HR 0.74; 95% CI 0.66–0.83) 
[35]. Therefore, there is a class IIa indication for the use of 
ivabradine in patients who are symptomatic with HFrEF, once 
they have been optimised on ARNIs, b-blockers, and MRAs. 
In summary, it is recommended that all patients with HFrEF 
be initiated and up-titrated on ACEIs and b-blockers to their 
target doses, and diuretics to signs or symptoms of decompensa-
tion. For patients who are still symptomatic, it is recommended 
that MRAs be added and maintained at target doses. Those who 
remain symptomatic with NYHA class II or worse symptoms 
and reduced ejection fraction should be switched from ACEIs 
to ARNIs. This requires a washout period of 36 h after cessation 
of ACEI therapy to prevent angioedema. The sacubitril com-
ponent inhibits neprilysin, and this culminates in angioedema, 
particularly in patients who are on an ACEI. Contraindications to 
the use of ARNIs are a glomerular filtration rate < 30 mL/min, 
severe liver dysfunction, a history of angioedema, and hypo-
tension with a systolic blood pressure < 90 mmHg. Patients 
should be monitored for hypotension, hyperkalaemia, and 
renal dysfunction. For those patients who are symptomatic 
on maximally tolerated doses of these medications and with 
a heart rate > 70 bpm, ivabradine could be considered as 
an add-on therapy, keeping in mind that this is only a class 
IIa recommendation based on a single RCT [36]. A primary 
prophylactic ICD should be considered in patients with an 
LVEF < 35% and NYHA class II–III symptoms despite optimal 
medical therapy for three months. In addition, patients who 
have normal sinus rhythm, a QRS duration of at least 150 ms, 
and a left bundle branch block pattern on electrocardiography 
should be considered for CRT [37, 38]. 
Heart failure with preserved ejection fraction (HFpEF) is 
as prevalent as HFrEF but differs in the pathophysiology from 
HFrEF, with little evidence to date to support specific treat-
ments [39, 40]. Strategies include managing volume and ad-
dressing underlying risk factors including hypertension, atrial 
fibrillation, and obesity. The TOPCAT trial [41] demonstrated 
a reduction in HF hospitalisations with spironolactone in 
HFpEF. There is no evidence of harm with the use of classes 
of medications that have been proved effective in HFrEF, so in 
patients who are hypertensive, have ischaemic heart disease, 
or require rate control for atrial fibrillation, b-blockers, ACEIs, 
and/or MRAs may be considered.
B-type natriuretic peptides (BNPs) can help detect 
decompensated HF. Rehospitalisation for HF is typically 
preceded by an elevation in left ventricular filling pressures 
that precede the clinical sequelae of HF by two to three 
weeks. BNPs are sensitive to perturbations in haemodynam-
ics. The levels of cardiac biomarkers including natriuretic 
peptides and cardiac troponins may also predict readmis-
sion risk and guide titration of therapies to improve clinical 
outcomes [42–46]. However, the GUIDE-IT trial [47] did 
not show a reduction in HF hospitalisation or cardiovascular 
mortality among patients with HFrEF who received therapies 
titrated to biomarker levels.
Healthcare services
Healthcare services such as exercise training and cardiac re-
habilitation have been shown to improve clinical outcomes in 
meta-analyses. A Cochrane systematic review of RCTs compar-
ing exercise-based interventions to no exercise demonstrated 
a trend to decrease mortality in the long term with the use 
of exercise therapy (risk ratio 0.88; 95% CI 0.75–1.02) [48]. 
Compared with control, exercise training reduced the rate 
of all hospitalisations (risk ratio 0.75; 95% CI 0.62–0.92) and 
HF hospitalisation (risk ratio 0.61; 95% CI 0.46–0.80) [48]. 
Transitional care services that bridge the gap as patients 
transition between healthcare settings and clinicians (from 
hospital to home) can also improve clinical outcomes. In 
a network meta-analysis of 54 RCTs that assessed the efficacy 
of transitional care services in patients hospitalised for HF, 
provided ≥ one month of follow-up, and reported all-cause 
mortality or all-cause readmissions [49], nurse home visits, 
disease management clinics, and nurse case management 
(a nurse-led initiative that begins in a hospital and continues 
through to the post-discharge phase) improved clinical out-
comes relative to other services following hospital discharge 
[49]. Among services that significantly decreased all-cause 
mortality compared with usual care, nurse home visits were 
most effective (RR 0.78; 95% CI 0.62–0.98), followed by 
disease management clinics (RR 0.80; 95% CI 0.67–0.97). 
Among services that significantly decreased all-cause 
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readmission, nurse home visits were most effective (incident 
rate ratio [IRR] 0.65; 95% CI 0.49–0.86), followed by nurse 
case management (IRR 0.77; 95% CI 0.63–0.95) and disease 
management clinics (IRR 0.80; 95% CI 0.66–0.97). Nurse 
home visits had the greatest pooled cost-savings [48]. How 
to practically implement these services within healthcare 
systems, however, is unclear. In a pragmatic stepped-wedge 
cluster randomised trial within a publicly funded healthcare 
system, a transitional care model combining self-care educa-
tion, multidisciplinary care, and, among high-risk patients, 
post-discharge nurse-led home visits and outpatient care in 
disease management clinics, did not improve the primary 
outcome of time to composite all-cause death, readmission, 
or emergency department visits at three months (HR 0.99; 
95% CI 0.83–1.19). However, it was associated with improved 
secondary patient-reported outcomes of discharge prepared-
ness, quality of care, and quality of life [50, 51]. 
Addressing advanced HF
There is a sharp increase in the risk of HF admissions in 
the last 30–60 days before death. Retrospective data from 
300,000 patients in Ontario, Canada revealed that the greatest 
cost of HF care occurs in the last months (six to eight weeks) of 
life. The care that is provided in hospitals is often discordant 
with patients’ values and preferences. Recognising advanced 
or end-stage HF can help facilitate timely referral for mechani-
cal circulatory support and transplant. Patients with advanced 
HF experience hypotension, require large doses of intrave-
nous diuretics, and experience frequent defibrillator shocks, 
recurrent hospitalisations, intolerance to their guideline-based 
medical therapy, and progressive worsening of their functional 
status. Such patients may have a progressive decline in renal 
function and hyponatraemia. Among patients who do not 
qualify for these therapies and continue to deteriorate despite 
best evidence-informed invasive and medical-guided therapy, 
it is important to initiate conversations about values, prefer-
ences, and end-of-life care planning [52]. The latter should 
include a discussion regarding the patient’s goals of care and 
palliative care interventions, such as deactivating ICDs so that 
patients do not experience refractory shocks, managing dysp-
noea that may require opioid therapy, managing psychosocial 
and spiritual distress, implementing home care supports, and 
referring patients to a hospice, which is frequently inaccessible 
to patients with HF [53].
Addressing comorbidities
The burden of cardiac and non-cardiac comorbidities among 
patients hospitalised for HF has been under-recognised. While 
efforts to improve outcomes following hospitalisation for HF 
have traditionally focused on improving HF care, optimal 
management of the patient who has been hospitalised for HF 
requires integrated, multidisciplinary care to address comorbidi-
ties that account for half of all readmissions. Policies that pe-
nalise institutions for readmissions following HF hospitalisation 
— in the absence of models of care that address both HF and 
its complex comorbidities in a manner that is patient-centred 
and clinically effective — are premature and unlikely to be 
successful in improving survival and quality of life.
SUMMARY
Approaches to improving outcomes in HF include: addressing 
the underlying cause; optimising medical therapies, which 
include diuretics, ACEIs, b-blockers, MRAs, ARNIs, and in 
some patients ivabradine; considering CRT/ICD in candidates; 
optimising health services in the healthcare system, which may 
include rehabilitation or exercise therapy and transitional care 
services; referring selected patients to transplant or palliative 
care; and incorporating patients’ values and preferences 
throughout the care continuum, and particularly near the 
end of life.
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